Misvik Biology is a Finnish biotech company providing services to both academic laboratories and companies looking for access to high-throughput cell-based screening using imaging-based assay technologies. Misvik Biology’s solutions are based on multiparameter image cytometry in combination with specific biological readouts that can be used to provide quantitative systems level information about cellular processes in health and disease. Misvik Biology’s solutions can be used to address strategic biomedical question in the areas of cancer, toxicology as well as basic cell biology.
Ex vivo therapy assessment for cancer is one of Misvik Biology’s applications allowing to identify clinically relevant drug sensitivities in ex vivo patient-derived cell cultures.
Learn more about Misvik Biology and their solution for ex vivo therapy assessment from the interview with CEO Juha Rantala using the link below.
For further information: http://www.misvik.com/